TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Aclarion Provides 2025 Update and 2026 Corporate Outlook

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Aclarion Provides 2025 Update and 2026 Corporate Outlook

Aclarion, a healthcare technology company, reported 69% year-over-year growth in Nociscan scan volumes for 2025, with Q4 showing 114% growth. The company maintains a debt-free balance sheet with $12.0 million in cash, providing runway into 2027. Aclarion is advancing its CLARITY clinical trial with plans to enroll 25% of patients by Q2 2026 and expects initial interim data in Q3 2026. The company added 9 new imaging centers and 22 physician users in 2025, and published clinical evidence supporting Nociscan's cost-effectiveness.

Insights
ACON   positive

Strong commercial momentum with 69% annual and 114% Q4 year-over-year scan volume growth, successful capital raise of $22M, debt-free balance sheet with sufficient runway into 2027, expanding clinical evidence base, growing provider network (9 new imaging centers, 22 new physicians), and advancing CLARITY trial with clear milestones. These factors demonstrate solid execution and investor confidence in the company's growth trajectory.